Tuberculosis Treatment Market Trends 2022

TEXAS CITY, Texas - Nov. 1, 2022 - PRLog -- The global tuberculosis treatment market size was valued at USD 1.7 billion in 2021, growing at a CAGR of 6.1% from 2022 to 2028.  A surge in drug susceptible (DS) tuberculosis (TB), as well as an upsurge in multi-drug resistant (MDR) TB cases and augmented R&D activities toward medication discovery, are expected to drive the Tuberculosis Treatment market expansion. Furthermore, a solid product pipeline for TB medicines, as well as increased government activities in emerging nations for tuberculosis treatment, provide considerable scope for market expansion in the coming years. The TB medicines industry is being driven by the rising frequency of multi-drug resistant tuberculosis. Drug shortages are a serious impediment to the TB drug market, particularly in low- and middle-income nations. Tuberculosis is particularly difficult to treat when it is linked with illnesses like HIV/AIDS and factors like overweight. Around a third of the world's population has latent TB; persons infected with mycobacterium infection have a 10% chance of getting tuberculosis; although, people with impaired immunity, such as HIV, diabetes, or cigarette addiction, have a greater chance of contracting tuberculosis. On the basis of the severity of the sickness, medicines used to treat TB are classified as first line treatment or second line treatment.

View Detailed Report Description at https://precisionbusinessinsights.com/market-reports/tuberculosis-treatment-market/

The global tuberculosis treatment market segmentation:

1) By Class of Drugs: First Line Drugs, Second Line Drugs)

2) By TB: B, Multi-Drug Resistance TB

3) By route of administration: Oral, Parental

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others

Asia Pacific led the market, with a share of x percent. This is due to the disease's higher incidence, rising prevalence of HIV-TB co-infection, greater public knowledge of the dangers of drug non-compliance, and improved health systems. In terms of API production, China and India are major players in the APAC industry.

There are several industry players working in the tuberculosis treatment market, which include Bayer AG (Germany), AstraZeneca PLC (U.S.), GlaxoSmithKline PLC (U.S.), Eli Lilly And Company (U.S.), Novartis AG (Switzerland ), Lupin Pharmaceuticals Inc. (India), Sandoz International GmbH (Germany), Pfizer Inc. (U.S.), Johnson & Johnson Services Inc. (U.S.), Sanofi S.A. (France)